DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves premarket: Pfizer, Disney, Tesla, Alibaba and more
▼ + stars: | 2023-12-01 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Pfizer — Shares dropped 4.2% after the drugmaker said it would halt development of its twice-daily experimental weight loss pill. Marvell Technology — The semiconductor stock fell more than 5% after Marvell issued lower-than-expected revenue guidance for the fourth quarter. Ulta Beauty — The stock gained nearly 12% after the beauty products retailer reported third-quarter earnings that beat analysts' expectations. Ulta reported earnings of $5.07 per share, higher than the $4.95 per share analysts polled by LSEG were expecting. Dell — Stock in the computer maker fell nearly 6% on the heels of a mixed third-quarter earnings report.

Persons: Pfizer, Andrew Nowinski, Nelson Peltz, Alibaba, Morgan Stanley, Tesla, Coinbase, Ulta, LSEG, Jessica Fye, Lisa Kailai Han, Jesse Pound, Michelle Fox Organizations: Pfizer —, Paramount Global, Wall Street Journal, Apple, Disney —, Trian Fund Management, Marvell Technology, Marvell, Invest, Nasdaq, Dell —, Wall, LSEG, JPMorgan Locations: —, Wells Fargo

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. But Novo and Pfizer are also trying to develop pill versions that would be easier for patients to take. Pfizer said it saw patient discontinuation rates topping 50% across all doses in a mid-stage study of twice-daily danuglipron. It ranged from nearly 7% to more than 11% in patients taking the pills. By comparison, obese patients without diabetes lost about 18% of their weight compared to a placebo when taking taking Eli Lilly’s Zepbound in late-stage research.

Persons: Eli Lilly, Eli Lilly’s Zepbound, Mikael Dolsten Organizations: Pfizer, Novo Nordisk, Novo, Drug Administration, Pfizer Inc Locations: York

☆ AbbVie to buy cancer drugmaker ImmunoGen for $10 billion as Humira faces heat
▼ + stars: | 2023-11-30 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Brian Snyder/File Photo Acquire Licensing RightsNov 30 (Reuters) - AbbVie (ABBV.N) will buy ImmunoGen (IMGN.O) for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to buy a developer of 'guided missile' cancer therapies as the company's top-seller Humira grapples with fierce competition. ImmunoGen's Elahere belongs to a new class of treatments called antibody-drug conjugates (ADC) that precisely targets cancer cells, potentially reducing toxicity for other cells. The drug, approved for ovarian cancer patients who have received previous therapies, is also being tested in earlier lines of treatment. AbbVie will also get access to Immunogen's follow-on pipeline of ADCs, including early-stage ovarian cancer candidate IMGN-151 and a mid-stage drug pivekimab sunirine for a rare type of blood cancer. Meanwhile, AbbVie's cancer drugs sales declined more than 8% in the third quarter to $1.51 billion, primarily due to increased competition to Imbruvica.

Persons: Brian Snyder, ImmunoGen's Elahere, AbbVie, IMGN, pivekimab, Immuogen stock's, Immunogen's, Elahere, Imbruvica, Manas Mishra, Leroy Leo, Shinjini Ganguli Organizations: REUTERS, Pfizer, Merck, U.S, Thomson Locations: Cambridge , Massachusetts, U.S, Bengaluru

☆ Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +10 min

In this article PFEMRNANVAX Follow your favorite stocks CREATE FREE ACCOUNTA sign advertises Covid vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, on Aug. 14, 2023. Brian Snyder | ReutersThree years into the Covid-19 pandemic, few Americans are rolling up their sleeves to get a Covid vaccine. Experts and vaccine makers can agree that low Covid vaccination rates are concerning, even as cases of the virus dwindle from their pandemic highs. However, Iovine of the University of Florida doesn't believe combination shots will have a significant effect on Covid vaccination rates. If combination shots don't do the trick, it's unclear what else could boost Covid vaccination rates down the line.

Persons: Brian Snyder, Ali Mokdad, Mokdad, Irfan Khan, Jennifer Kates, Brad Pollock, Nicole Iovine, epidemiologist, Iovine, Michael Yee, Albert Bourla, Arpa Garay, Garay, John Trizzino, Trizzino, Jamey Mock, Andrew Pekosz, Jefferies, Yee, doesn't Organizations: Walgreens, Reuters, Pfizer, Moderna, Centers for Disease Control, CDC, University of Washington, CVS Pharmacy, Los Angeles Times, KFF, UC Davis Health's, University of Florida, Jefferies, Arpa, CNBC, Istock, Getty, Johns Hopkins Bloomberg School of Public Health Locations: Somerville , Massachusetts, U.S, Novavax, Covid, Eagle Rock , California

[1/4] Employees work in the manufacturing of Pfizer’s new respiratory syncytial virus (RSV) vaccine Abrysvo, in this undated handout picture. Pfizer/Handout via REUTERS Acquire Licensing RightsWASHINGTON, Nov 28 (Reuters) - Senior Biden administration officials met with RSV vaccine makers this week to underscore the need for manufacturers such as Sanofi (SASY.PA) and AstraZeneca (AZN.L) to urgently meet demand as winter approaches, the White House said on Tuesday. At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the vaccines targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults. "Monday's meeting follows numerous in-person and virtual meetings to seek ways manufacturers can make more RSV immunizations available for infants," the White House said in a statement. Reporting by Susan Heavey and Ahmed Aboulenein; Additional reporting by Mike Erman; Editing by Katharine Jackson and Nick ZieminskiOur Standards: The Thomson Reuters Trust Principles.

Persons: Susan Heavey, Ahmed Aboulenein, Mike Erman, Katharine Jackson, Nick Zieminski Organizations: Pfizer, Handout, REUTERS Acquire, Rights, Biden, Sanofi, AstraZeneca, White, U.S . Centers for Disease Control, Prevention, CDC, Thomson Locations: U.S

☆ Pfizer to cut 500 jobs at UK site as part of wider cost cuts
▼ + stars: | 2023-11-14 | by ( ) www.reuters.com time to read: +1 min

Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/ File Photo Acquire Licensing RightsNov 14 (Reuters) - Pfizer (PFE.N) will cut 500 jobs at its Sandwich, Kent site in the U.K. as part of its $3.5 billion cost-cutting plan, the drugmaker said on Tuesday. The U.S. drugmaker announced the cost-cutting program in October after slashing its full-year revenue forecast due to lower-than-expected sales of its COVID-19 vaccine and treatment. Pfizer, which employs roughly 83,000 people globally, has not disclosed how many jobs will be affected by the cost-reduction program. The company said on Tuesday it would share further details on the program as part of the full-year forecast for 2024.

Persons: Johanna Geron, drugmaker, Christy Santhosh, Shailesh Kuber Organizations: Pfizer, REUTERS, Thomson Locations: Puurs, Belgium, Sandwich, Kent, U.S

More than 3,700 babies were born with congenital syphilis in 2022 — 10 times more than a decade ago and a 32% increase from 2021, the Centers for Disease Control and Prevention said Tuesday. The 2022 count was the most in more than 30 years, CDC officials said, and in more than half of the congenital syphilis cases, the mothers tested positive during pregnancy but did not get properly treated. The rise in congenital syphilis comes despite repeated warnings by public health agencies and it’s tied to the surge in primary and secondary cases of syphilis in adults, CDC officials said. It’s also been increasingly difficult for medical providers to get benzathine penicillin injections — the main medical weapon against congenital syphilis — because of supply shortages. Nearly 40% of last year’s congenital syphilis cases involved mothers who didn't have prenatal care, the CDC said.

Persons: it’s, It’s, Laura Bachmann, “, Mike Saag, ”, Nina Ragunanthan, ___ Hunter, Robert Wood Johnson Organizations: Centers for Disease Control, Prevention, CDC, Federal, Associated, University of Alabama, OB, Delta Health Center, Pfizer, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, Robert Wood Johnson Foundation, AP Locations: U.S, Illinois, Birmingham, Mound Bayou , Mississippi, Atlanta

☆ Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
▼ + stars: | 2023-10-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Tuesday reported a narrower-than-expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and the Covid vaccine. Pfizer said it recorded a $5.6 billion charge for inventory write-offs in the third quarter due to lower-than-expected use of Covid products. Of these write-offs, $4.7 billion is chalked up to Paxlovid and $900 million is attributed to the company's vaccine. For the third quarter, Pfizer booked a net loss of $2.38 billion, or 42 cents per share. Meanwhile, the pharmaceutical giant expects its Covid antiviral treatment Paxlovid to bring in $1 billion in revenue.

Persons: Paxlovid Organizations: Pfizer, LSEG, U.S . Locations: U.S, Monday's

☆ Pfizer can recover from its post-Covid fatigue
▼ + stars: | 2023-10-31 | by ( ) www.reuters.com time to read: +2 min

Pfizer reported plummeting demand for its Covid vaccines and treatments, with an overall revenue decline of over 40% compared to last year, and a $2.4 billion loss that included a $5.6 billion charge for Covid inventory write-offs. Pfizer now thinks 2023 revenue from shots and pills for the disease will total about $12.5 billion, over a 75% decrease from last year. Peers trade at around 5 times sales, and if Pfizer did too its enterprise value would be about $235 billion. Instead it’s almost 20% less, and the stock is worth one-fifth less than it was at the end of 2019. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Ivan Alvarado, It’s, Peers, it’s, What’s, Robert Cyran, John Foley, Aditya Sriwatsav Organizations: Pfizer, REUTERS, Reuters, Covid, X, Vodafone, Thomson Locations: Santiago , Chile, Spain

☆ Pfizer RSV vaccine lags GSK’s as head-to-head competition underway
▼ + stars: | 2023-10-30 | by ( Michael Erman | ) www.reuters.com time to read: +4 min

[1/3] View of Pfizer's new respiratory syncytial virus (RSV) vaccine Abrysvo during its manufacture in this undated handout picture. "800 POUND GORILLAS"CVS, which has more than 9,000 U.S. locations, declined to comment on why it was only carrying GSK's vaccine. It was not immediately clear how many RSV shots were being administered in pharmacies versus doctors' offices. GSK declined to discuss its RSV vaccine contracts, but said customer relationships gives it a competitive advantage. Two independent pharmacists said they are being charged a lower price by wholesalers for the GSK vaccine, which comes in boxes of 10.

Persons: Price, Ben Link, Link, Pfizer's, Dovato, Morningstar, Damien Conover, We’ve, Alison Hunt, Michelle Vargas, Michael Erman, Caroline Humer, Bill Berkrot Organizations: Pfizer, Handout, REUTERS, GSK, Reuters, CVS Health, CVS, Walgreens, Walmart, Aid, Thomson Locations: United States, British, U.S, South Carolina

WASHINGTON (AP) — The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag. Pharmaceutical giant Pfizer is setting the price for a five-day treatment of Paxlovid at $1,390, but Americans can still access the pills at no cost -- for now. The less commonly used COVID-19 treatment Lagevrio, manufactured by Merck, also will hit the market next week. People on private insurance may start to notice copays for the treatments once their pharmacy or doctor's office runs out of the COVID-19 treatments they received from the government. Full-year revenue for Paxlovid and Pfizer's COVID-19 vaccine, Comirnaty, is expected to be approximately $12.5 billion.

Persons: “ Pfizer, Paxlovid, coronavirus, Pfizer's, “, Tom Murphy Organizations: WASHINGTON, Pharmaceutical, Pfizer, Merck, Health, Human Services, The Department of Veterans Affairs, Department of Defense, Indian Health Service, U.S, Associated Press, and Drug Administration, Paxlovid Locations: U.S, Indianapolis

☆ Debunking claims that a 'cartel' of asset managers controls major U.S. corporations
▼ + stars: | 2023-10-23 | by ( Ryan Ermey | ) www.cnbc.com time to read: +2 min

If you look up the top institutional investors in these firms, you will find major asset managers close to the top of the list. 2, and State Street is No. State Street, Vanguard and BlackRock are the top shareholders in Lockheed, in that order. Pfizer's top shareholders: Vanguard, BlackRock and State Street. That's because BlackRock makes money by collecting fees from its investors, not by reaping profits from the companies it invests in.

Persons: Lockheed Martin, Daniel Sotiroff Organizations: Apple, Lockheed, Pfizer, Vanguard, BlackRock, Morningstar Research Services, State Locations: BlackRock

☆ Merck’s cancer rush may spawn lower returns
▼ + stars: | 2023-10-20 | by ( ) www.reuters.com time to read: +2 min

The American drug company said on Thursday it signed a giant deal with Daiichi Sankyo (4568.T) for the rights to sell three potential drugs outside Japan. Merck will pay $4 billion upfront, up to another $1.5 billion over the next two years, and as much as $16.5 billion if the drugs pass certain sales milestones. Merck’s Keytruda accounts for about 40% of the company’s revenue, and that cancer drug might face cut-price competition before the end of the decade. The potential is giant, as these targeted therapies might eventually account for a quarter of the current oncology market. With over 100 of these drugs in clinical trials, the stampede might lead to lower-than-expected returns.

Persons: Jeff Zelevansky, Robert Cyran, Jean, Pierre Mustier, Atos, Jennifer Saba, Aditya Sriwatsav Organizations: Merck & Co, REUTERS, Reuters, Merck, Pfizer, X, News Corp, Thomson Locations: Linden , New Jersey, American, Japan

☆ Pfizer to price Covid drug Paxlovid at $1,390 per course
▼ + stars: | 2023-10-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year. A company spokesperson on Wednesday confirmed the price, which was first reported by The Wall Street Journal. But beginning in 2024, Pfizer will sell Paxlovid directly to health insurers, which comes as demand for Covid vaccines and treatments slumps nationwide. But health insurance plans will likely pay much less than the nearly $1,400 list price for Paxlovid, meaning patients will probably have small or no out-of-pocket costs. Overall, Pfizer now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion.

Persons: Angelica Peebles Organizations: Pfizer, Wednesday, Wall Street, Paxlovid, FDA, CNBC Locations: Paxlovid

☆ Pfizer gets upgrade at Jefferies, which says there's a buying opportunity in the pharma giant's stock
▼ + stars: | 2023-10-16 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Jefferies thinks its time for investors to go long on Pfizer . "In our view, PFE has one of the most intriguing catalyst paths over the next yr in large cap pharma and trades ~15% below where it traded at the start of the COVID pandemic." The analyst added Pfizer has already presented "an impressive innovation framework" that has helped the company adapt to healthcare headwinds, which underpinned the bullish long-term view. "During the pandemic, Pfizer in collaboration with Biontech rolled out COVID vaccines in a historical timeframe. PFE YTD mountain Pfizer stock YTD — CNBC's Michael Bloom contributed to this report.

Persons: Jefferies, Akash Tewari, it's, Tewari, PFE, Biontech, Paxlovid, Michael Bloom Organizations: Pfizer, pharma

☆ Stocks making the biggest moves midday: Lululemon, Pfizer, News Corp, Charles Schwab and more
▼ + stars: | 2023-10-16 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Pfizer — Shares rallied 3.61% following an upgrade by Jeffries to buy from hold. The firm sees an attractive buying opportunity after Pfizer cut its full-year guidance last week on slumping vaccine sales. Alignment Healthcare — Shares soared 17.22% after being upgraded to strong buy from outperform by Raymond James. Tal Education — The education technology stock popped 6.73% after UBS upgraded shares to a buy rating, citing an attractive valuation and tailwinds from Tal Education's nonacademic tutoring business. Greenbrier — Shares of the transportation services company gained 3.81% Monday morning after Susquehanna upgraded the stock to a positive rating.

Persons: Dow, Lululemon, Jeffries, Novavax, Raymond James, Morgan Stanley, Jim Ratcliffe, Sheikh Jassim bin Hamad al Thani, Glazer, Tal Education's, Charles Schwab —, Schwab, Albemarle —, Albemarle, Bascome, Henry Schein —, Yun Li, Fred Imbert, Hakyung Kim, Samantha Subin, Alex Harring, Pia Singh, Lisa Han Organizations: Dow Jones Indices, Activision, Microsoft, Pfizer —, Pfizer, Moderna, News Corp, Reuters, Street, Street Journal, Systems, Manchester United, Tal Education, UBS, Liontown, Greenbrier —, Susquehanna Locations: BioNTech, Greenbrier

☆ Stocks making the biggest moves premarket: Pfizer, Lululemon, Manchester United, Rite Aid and more
▼ + stars: | 2023-10-16 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Pfizer , Moderna , BioNTech — Shares of Pfizer dropped 1.3% after the company slashed its full-year revenue guidance by $9 billion, noting waning demand for its Covid treatment and vaccine. Following the guidance cut, Jefferies upgraded Pfizer on Monday, citing an attractive buying opportunity. Vaccine markers Moderna and BioNTech also dropped premarket, losing 4.1% and 5%, respectively. Colgate-Palmolive — The consumer products stock gained more than 1% in premarket trading after Stifel upgraded Colgate-Palmolive to buy from hold. The firm cited the stock's attractive valuation and the rapid and profitable growth of TAL's non-academic tutoring business as catalysts.

Persons: Jefferies, BioNTech, premarket, Morgan Stanley, Jim Ratcliffe, Jeffrey Stein, Dow, Charles Schwab, CNBC's Hakyung Kim, Jesse Pound, Tanaya Macheel, Michelle Fox Theobald, Lisa Han Organizations: Pfizer, Moderna, BioNTech, Colgate, Palmolive, Manchester United, Wall Street, . Rite, Dow Jones, Activision, Microsoft, TAL Education Group, UBS Locations: New Jersey

☆ Stock Market Today: Dow Futures Edge Up; Investors Eye Lululemon, Pfizer
▼ + stars: | 2023-10-16 | by ( ) www.wsj.com time to read: 1 min

The rush to haven assets has abated, but investors remained on edge about the potential for an escalation in the Israel-Hamas conflict to ripple through markets and the world economy. Stock futures edged up, as did Treasury yields. Follow live updates on the conflict here. Lululemon Athletica’s stock gained ground in premarket trading, two days before it will join the S&P 500 index. Pfizer and other Covid-19 vaccine makers' stocks fell after the pharma giant cut its sales outlook.

Persons: paring, Fighting Organizations: Investors, Pfizer, pharma Locations: Israel, Gaza, Lebanon

☆ Pfizer slashes revenue forecast on lower COVID sales, will cut costs
▼ + stars: | 2023-10-13 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

Pfizer and rivals have begun selling an updated COVID vaccine for this fall. The drugmaker said it now expects 2023 revenue of between $58 billion and $61 billion, down from its prior forecast of $67 billion to $70 billion. It had previously expected Paxlovid revenue of about $8 billion for the year. Pfizer also cut full-year revenue expectations for the COVID vaccine by about $2 billion due to lower-than-expected vaccination rates. Pfizer said its non-COVID products remain on track to achieve 6% to 8% revenue growth year over year in 2023.

Persons: Albert Boura, Michael Erman, Sriparna Roy, Bill Berkrot, Rod Nickel Organizations: Pfizer, U.S ., Strategic, Thomson Locations: York, New Jersey, Bengaluru

☆ New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
▼ + stars: | 2023-10-13 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Two new immunizations promise to protect babies from respiratory syncytial virus – if people can find them. Providers are scrambling to offer Pfizer's vaccine, Abrysvo, to pregnant patients and Sanofi's monoclonal antibody, Beyfortus, to babies. Until now, the only preventative treatment was another monoclonal antibody called Synagis that's given once a month during RSV season, which generally runs from fall through spring. Sanofi's Beyfortus is a monoclonal antibody that's given directly to babies and provides them with immediate protection. "I know that [RSV]'s a threat to little babies, and so to have an opportunity to prevent illness in the first place is really exciting."

Persons: Michael Chamberlin, hasn't, we're, Chamberlin, that's, Erin Bakke, Graham Organizations: Pediatric Associates Locations: Carmel, Cincinnati , Ohio

☆ Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump
▼ + stars: | 2023-10-13 | by ( Jacob Pramuk | ) www.cnbc.com time to read: +1 min

Pfizer slashed its full-year earnings and revenue guidance on Friday, as it said demand for its Covid products has waned. The company now expects 2023 sales of $58 billion to $61 billion, down from its previous guidance of $67 billion to $70 billion. Pfizer said it cut its revenue outlook "solely due to its Covid products." The biopharmaceutical company slashed its full-year adjusted earnings guidance to a range of $1.45 to $1.65 per share, from a previous $3.25 to $3.45 per share. It also said it anticipates sales of its vaccine, Comirnaty, will be $2 billion lower than previously expected because of lower-than-expected vaccination rates.

Persons: Albert Bourla Organizations: Pfizer, European Commission, BioNTech, U.S ., CNBC, YouTube Locations: U.S, Puurs, Belgium

☆ Covid-induced Nobel Prize is on brand
▼ + stars: | 2023-10-02 | by ( Robert Cyran | ) www.reuters.com time to read: +4 min

They realized that modifying lab-made mRNA, a molecule used for protein production, nearly stopped the body from mounting an inflammatory response. It takes, on average, about 25 years between publishing work and receiving the Noble Prize in medicine. There are exceptions: insulin was created in 1921, administered to children in 1922, and the inventors were given the prize in 1923. Contrast that to Ralph Steinman, awarded the prize in Medicine in 2011 for work done in 1973. Follow @rob_cyran on XCONTEXT NEWSKatalin Kariko and Drew Weissman were awarded the Nobel Prize in Medicine on Oct. 2 for their work in a paper published in 2005 in the journal Immunity on mRNA molecule modifications.

Persons: Kariko, Drew Weissman, Ralph Steinman, Germany’s, Weissman, Lauren Silva Laughlin, Aditya Sriwatsav Organizations: Reuters, University of Pennsylvania, Medicine, U.S . Defense Department, Pfizer, Moderna, Thomson Locations: Covid

☆ CDC advisors recommend Pfizer maternal RSV vaccine to protect infants
▼ + stars: | 2023-09-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer's vaccine, called Abrysvo, is already approved and available in the U.S. for adults ages 60 and up. The panel's recommendation puts Pfizer's maternal shot on track to reach the public as RSV begins to spread at higher levels. But younger children and older adults are particularly vulnerable to more severe RSV infections. Each year, the virus kills a few hundred children younger than 5, and 6,000 to 10,000 seniors, according to the CDC. RSV also causes around 58,000 to 80,000 hospitalizations among children younger than 5 years old each year, the CDC said.

Persons: Pfizer, Mandy Cohen, Luis Jodar, Pfizer's Abrysvo, Jefferson Jones, Jones Organizations: Disease Control, U.S, Public, CDC, Pfizer, Northern, Drug Administration, FDA, AstraZeneca Locations: U.S, Sanofi

MILWAUKEE (AP) — Some people seeking the newest COVID-19 vaccine are running into high demand, insurance headaches and supply delays coast to coast. But some people have had to cancel appointments because their insurance hasn’t updated the billing codes to cover the vaccines. And in some places, there are no available nearby vaccines: A search in Juneau, Alaska, through the federal government’s website shows no available appointments within 100 miles. For others, the shots were covered by insurance without issue, but appointments were canceled by their pharmacy due to supply delays. Walgreens and CVS confirmed that delivery delays to some stores across the country had led to canceled appointments.

Persons: Cases, Alex Huseman, ” Huseman, Matt Blanchette, “, Pfizer spokespeople, Chris Ridley, Marwa Bakr, ” Bakr, Karen Ramos, ” Ramos, ”, Robert Wood Johnson Organizations: MILWAUKEE, for Disease Control, Prevention, Alaska Department of Health, CVS, Walgreens, ” Moderna, Pfizer, Associated Press, Associated Press Health, Science Department, Robert Wood Johnson Foundation, AP Locations: Juneau , Alaska, Moderna, Temecula , California, Caribbean, San Diego, Temecula

Search resuls for: ". Pfizer"

25 mentions found